Similarly, ADAM17 activates the EGFR-PI3K-AKT pathway in glioma, resulting in enhanced proliferation, invasion, and angiogenesis, and inhibition of ADAM17, which significantly reduce tumour growth in mice [108]. Here, EGFR is linked to neoplasm.